<div>Navidea Biopharmaceuticals, Inc. (OTC: NAVB), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced disappointing results of an exploratory analysis conducted on the company’s pivotal NAV3-33 clinical trial. Dr. Michael Blue, Navidea’s Chief Medical Officer, said &#34;Results are not indicative of a commercially viable product.”<br>
<br>
Ekinops (Euronext Paris: EKI) (ISIN: FR0011466069), a leading supplier of optical transport and enterprise connectivity solutions for telecom operators and enterprises, today announced that Orange Business has chosen Ekinops technology to launch its new SD-WAN offer named SD-WAN Essentials, transforming Enterprise connectivity into a stepping stone to the Cloud.<br>
<br>
For more information, please visit <a href="http://stockdaymedia.com/" rel="nofollow">StockDayMedia.com</a>
</div>
<br/><br/>Advertising Inquiries: <a href='https://redcircle.com/brands'>https://redcircle.com/brands</a><br/><br/>Privacy & Opt-Out: <a href='https://redcircle.com/privacy'>https://redcircle.com/privacy</a>

<description>&lt;div&gt;Navidea Biopharmaceuticals, Inc. (OTC: NAVB), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced disappointing results of an exploratory analysis conducted on the company’s pivotal NAV3-33 clinical trial. Dr. Michael Blue, Navidea’s Chief Medical Officer, said &amp;#34;Results are not indicative of a commercially viable product.”&lt;br&gt;
&lt;br&gt;
Ekinops (Euronext Paris: EKI) (ISIN: FR0011466069), a leading supplier of optical transport and enterprise connectivity solutions for telecom operators and enterprises, today announced that Orange Business has chosen Ekinops technology to launch its new SD-WAN offer named SD-WAN Essentials, transforming Enterprise connectivity into a stepping stone to the Cloud.&lt;br&gt;
&lt;br&gt;
For more information, please visit &lt;a href="http://stockdaymedia.com/" rel="nofollow"&gt;StockDayMedia.com&lt;/a&gt;
&lt;/div&gt;
&lt;br/&gt;&lt;br/&gt;Advertising Inquiries: &lt;a href='https://redcircle.com/brands'&gt;https://redcircle.com/brands&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;Privacy &amp; Opt-Out: &lt;a href='https://redcircle.com/privacy'&gt;https://redcircle.com/privacy&lt;/a&gt;</description>

<div>Navidea Biopharmaceuticals, Inc. (OTC: NAVB), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced disappointing results of an exploratory analysis conducted on the company’s pivotal NAV3-33 clinical trial. Dr. Michael Blue, Navidea’s Chief Medical Officer, said "Results are not indicative of a commercially viable product.”<br>
<br>
Ekinops (Euronext Paris: EKI) (ISIN: FR0011466069), a leading supplier of optical transport and enterprise connectivity solutions for telecom operators and enterprises, today announced that Orange Business has chosen Ekinops technology to launch its new SD-WAN offer named SD-WAN Essentials, transforming Enterprise connectivity into a stepping stone to the Cloud.<br>
<br>
For more information, please visit <a href="http://stockdaymedia.com/">StockDayMedia.com</a>
</div>


Advertising Inquiries: https://redcircle.com/brands

Privacy & Opt-Out: https://redcircle.com/privacy

Stock Day Media

Navidea Biopharmaceuticals, Inc. | Ekinops

Navidea Biopharmaceuticals, Inc. | Ekinops

Description